Truist Securities analyst Neal Dingmann upgrades Centennial Resource Dev (NASDAQ:CDEV) from Hold to Buy.
PMV Pharmaceuticals To Present Updated Phase 1 Data On PC14586 At The 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics And Host A KOL Webinar
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated
